Oral Arsenic-Containing Qinghuang Powder:A Potential Drug for Myelodysplastic Syndromes

作     者：MING Jing LIU Wei-yi XIAO Hai-yan XU Yong-gang MA Rou HU Xiao-mei MING Jing;LIU Wei-yi;XIAO Hai-yan;XU Yong-gang;MA Rou;HU Xiao-mei

作者机构：Department of HematologyXiyuan HospitalChina Academy of Chinese Medical SciencesBeijing100091China 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2022年第28卷第8期

页      面：762-768页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 100506[医学-中医内科学] 1005[医学-中医学] 1002[医学-临床医学] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China(No.81673821,81774142) Special Research Foundation of Central Level Public Scientific Research Institutes(No.ZZ10-016)。 

主　　题：arsenic Qinghuang Powder myelodysplastic syndromes review Chinese medicine 

摘      要：Qinghuang Powder(QHP),an oral arsenic,has become an effective drug in the treatment of myelodysplastic syndromes(MDS)in Xiyuan Hospital,China Academy of Chinese Medical Sciences for many years,and the action mechanism of the compound or active ingredient AsSof QHP has been elucidated.Considering the relatively safety,chemotherapy-free and convenient oral profile,QHP is widely used in the clinical treatment for MDS patients,especially for elderly patients.In this review,the authors document the efficacy and safety of oral arsenic-containing compound QHP in the treatment of MDS,with a special focus on the association of efficacy of QHP with the cytogenetics,prognostic risk,DNA methylation,gene mutation,blood arsenic concentration,mechanism of action of AsSand the countermeasures against adverse reactions of gastrointestinal tract.